188526-16-1

Basic information

• Product Name: benzyl 5-t-butyl-1,3-dioxolene-2-one-4-carboxylate
• Synonyms: benzyl 5-t-butyl-1,3-dioxolene-2-one-4-carboxylate
• CAS NO: 188526-16-1
• Molecular Weight: 276.289
• Mol File: 188526-16-1.mol

Chemical Properties

• CAS DataBase Reference: benzyl 5-t-butyl-1,3-dioxolene-2-one-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 5-t-butyl-1,3-dioxolene-2-one-4-carboxylate(188526-16-1)
• EPA Substance Registry System: benzyl 5-t-butyl-1,3-dioxolene-2-one-4-carboxylate(188526-16-1)

Safety Data

• Hazardous Substances Data: 188526-16-1(Hazardous Substances Data)

Upstream product

• 530-62-1 1,1'-carbonyldiimidazole 
• 188526-15-0 benzyl 4,4-dimethyl-2-hydroxy-3-oxopentanoate 
• 17094-34-7 ethyl pivaloylacetate 
• 3282-30-2 pivaloyl chloride 
• 77902-92-2 Benzyl γ,γ-dimethyl-β-oxovalerate 
• 188526-14-9 [1-(benzyloxy)-4,4-dimethyl-1,3-dioxopentan-2-yl]diazen-2-ium-1-ide 
• 64269-79-0 Carbonyldiimidazole 
• 100-51-6 benzyl alcohol 
• 55107-14-7 Methyl 4,4-dimethyl-3-oxopentanoate 

Relevant articles and documents

COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY

The present invention provides compounds having superior TAFIa inhibitory activity. They are dihydroimidazoquinoline compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: (I) wherein R is a hydrogen atom or a Cs

HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES

The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

A general synthesis of dioxolenone prodrug moieties

A general method for the synthesis of dioxolenone prodrug moieties from appropriately substituted β-ketoesters is described. This novel and versatile sequence allows for the synthesis of alkyl- or aryl-substituted dioxolenone alcohols 8 or bromides 9. Coupling of the bromides 9 to prepare bis-dioxolenone phosphonate prodrug esters is also presented.